查看購物車
  • Simplified Chinese
  • English
  • Japanese
全球孕產婦保健市場 - 2023-2030
市場調查報告書
商品編碼
1352125

全球孕產婦保健市場 - 2023-2030

Global Maternal Health Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

2022年，全球孕產婦保健市場規模達141億美元，預計2030年將達283億美元，2023-2030年預測期間複合年成長率為8.5%。

孕產婦保健市場的推動因素包括意識和教育的提高、孕產婦年齡的上升、政府舉措、醫療保健基礎設施的不斷發展以及孕產婦心理健康的意識。

定期體檢、篩檢和測試是懷孕期間適當產前護理的一部分。透過及早發現和治療任何潛在問題，確保母親和正在成長的胎兒的健康。母親和未出生孩子的健康取決於良好均衡的飲食。胎兒的生長發育需要攝取足夠的必需營養素來支持，這也保護了母親的健康。

動力學

關鍵參與者之間日益加強的合作正在推動全球孕產婦保健市場的成長

2023 年 5 月，為了將孕產婦健康和泌尿學領域獨特且突破性的產品商業化，CORONA Remedies Private Limited (CORONA) 與 Ferring Pharmaceuticals Pvt. 簽訂了協議。有限公司（Ferring）是全球生物製藥公司 Ferring Pharmaceuticals 的子公司，總部位於瑞士。

CORONA 和 Ferring 之間的合作將為印度各地的患者提供尖端產品，其中一些產品將來自國際品牌，以滿足泌尿科和孕產婦健康方面未得到滿足的治療要求。他們很高興與研究驅動的專業生物製藥集團 Ferring 合作，為印度患者提供一流的藥物。

孕產婦保健資金的增加推動了全球孕產婦保健市場的成長

2023 年 1 月，位於泰米爾納德邦韋洛爾的基督教醫學院 (CMC) 現在擁有美國國際開發署 (USAID) 提供的先進模擬實驗室中心。該實驗室將用於培訓孕產婦和新生兒護理方面的醫療專業人員，包括心肺復甦術、基礎和高級護理技術以及解決孕產婦健康和新生兒緊急情況的最新技術。

美國國際開發署的美國海外學校和醫院 (ASHA) 計劃提供 100 萬美元贈款，資助高級模擬實驗室中心。 ASHA 致力於在美國人和印度人之間建立友好和互利的關係。由於病患安全、協議和匯報方法對於學生評估和回饋至關重要，因此該機構在這些領域採用了美國的最佳實踐。透過這項努力，美國國際開發署也為醫院的新生兒加護病房以及待產室提供了現代化的用品和設備。

孕產婦保健面臨的課題正在阻礙全球孕產婦保健市場的成長

許多地區在獲得高品質醫療保健服務方面存在差異，特別是對於服務不足的人群而言，這對孕產婦健康結果產生了負面影響。不良的產前護理可能源於對適當的孕產婦保健缺乏知識和理解，這可能會促使整個懷孕和分娩過程中出現問題。對於許多婦女，特別是低收入或未投保族群來說，高品質孕產婦保健服務（包括產前護理、分娩和產後護理）的費用可能令人望而卻步。

目錄

第 1 章：方法與範圍

  • 研究方法論
  • 報告的研究目的和範圍

第 2 章：定義與概述

第 3 章：執行摘要

  • 治療區隔
  • 依指示顯示區隔
  • 依配銷通路分類區隔
  • 依地區分類區隔

第 4 章：動力學

  • 影響因素
    • 動力
      • 主要參與者之間的合作不斷加強
    • 限制
      • 與孕產婦健康相關的課題
    • 機會
      • 技術進步
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 未滿足的需求
  • 監管分析

第 6 章：COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情況
    • COVID-19 期間的情況
    • COVID-19 後的情景
  • COVID-19 期間的定價動態
  • 供需譜
  • 疫情期間政府與市場相關的舉措
  • 製造商的策略舉措
  • 結論

第 7 章：俄羅斯-烏克蘭戰爭分析

第 8 章：人工智慧分析

第 9 章：透過治療

  • 荷爾蒙
  • 營養品
  • 止痛藥
  • 抗感染藥
  • 其他

第 10 章：依指示

  • 流產
  • 早產和分娩
  • 其他

第 11 章：依配銷通路

  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 12 章：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 亞太其他地區
  • 中東和非洲

第13章：競爭格局

  • 競爭場景
  • 產品基準化分析
  • 公司股份分析
  • 主要進展和策略

第 14 章：公司簡介

  • Johnson & Johnson
    • 公司簡介
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • Jiovio Healthcare
  • Pfizer Inc
  • GlaxoSmithKline Inc.
  • Merck & Co., Inc.
  • RAND Corporation
  • SYNAPSE Product Development
  • Siemens
  • Reckitt Benckiser Group Plc
  • Sanofi

第 15 章：附錄

簡介目錄
Product Code: PH6866

Overview

The Global Maternal Health Market reached US$ 14.1 billion in 2022 and is expected to reach US$ 28.3 billion by 2030 growing with a CAGR of 8.5% during the forecast period 2023-2030.

The maternal health market is driven by factors such as increasing awareness and education, rising maternal age, government initiatives, growing healthcare infrastructure and awareness of maternal mental health.

Regular medical check-ups, screenings, and testing are part of proper prenatal care during pregnancy. The health of the mother and the growing fetus is ensured through early detection and treatment of any potential issues. The health of the mother and the unborn child depends on eating a good and balanced diet. The growth and development of the fetus are supported by an adequate intake of necessary nutrients, which also protects the mother's health.

Dynamics

The Increasing Collaboration Among Key Players is Driving the Global Maternal Health Market Growth

In May 2023, in order to commercialize distinctive and ground-breaking products in the areas of Maternal Health & Urology, CORONA Remedies Private Limited (CORONA) entered into an agreement with Ferring Pharmaceuticals Pvt. Ltd. (Ferring), a subsidiary of global biopharmaceuticals company Ferring Pharmaceuticals with headquarters in Switzerland.

The partnership between CORONA and Ferring will provide patients all over India with cutting-edge products, some of which will be from international brands, to meet the unmet treatment requirements in urology and maternal health. They are thrilled to collaborate with Ferring, a research-driven, specialty biopharmaceutical group, to provide patients in India with top-notch medications.

The Increasing Funding for Maternal Health Boost The Global Maternal Health Market Growth

In January 2023, The Christian Medical College (CMC) in Vellore, Tamil Nadu, now has an advanced simulation lab center due to the U.S. Agency for International Development (USAID). The lab will be used to train medical professionals in maternal and neonatal care, including CPR, basic and advanced nursing techniques, and the newest technologies to address maternal health and newborn emergencies.

The American Schools and Hospitals Abroad (ASHA) program of USAID provides a $1 million (USD) grant to fund the Advanced Simulation Lab Center. ASHA works to create friendly and mutually beneficial relationships between Americans and Indians. Since patient safety, protocols, and debriefing methods are crucial for student evaluation and feedback, the institution adopts American best practices in these areas. Modern supplies and equipment for the hospital's neonatal critical care unit and labor and delivery rooms were also made possible by USAID through this effort.

Challenges with Maternal Health are Hampering the Global Maternal Health Market Growth

There are discrepancies in access to high-quality healthcare services in many areas, especially for underserved people, which has a negative impact on maternal health outcomes. Poor prenatal care can stem from a lack of knowledge and understanding about proper maternal health care, which could cause issues throughout pregnancy and childbirth. For many women, particularly in low-income or uninsured populations, the expense of high-quality maternal health services, including prenatal care, delivery, and postnatal care, can be prohibitive.

Segment Analysis

The global maternal health market is segmented based on treatment, indication, distribution channel, and region.

The Hormones Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The hormones segment accounted for the highest market stake accounting for approximately 45.4% of the maternal health market in 2022. Hormones and maternal health are tightly related during pregnancy and the postpartum period. The different physiological and mental changes that take place in a woman's body during pregnancy and after childbirth are significantly regulated by hormones.

For the mother's and the fetus's health to be maintained during pregnancy, specific hormones must be produced in greater quantities. The most notable hormones involved in pregnancy are progesterone, estrogen, human chorionic gonadotropin hormone (hCG), and human placental lactogen (hPL). A hormone called progesterone is essential for preserving the uterine lining and avoiding contractions. Progesterone supplements may occasionally be advised for women who have a history of recurrent miscarriages or who have a short cervix.

Geographical Penetration

North America Holds a Dominant Position in the Global Maternal Health Market

North America is estimated to hold around 1/3rd of the total market share throughout the forecast period. In October 2022, The Special Supplemental Nutrition Program for Women, Infants, and Children, or WIC, has undergone significant modernization and innovation, and the U.S. Department of Agriculture recognizes its accomplishment and promise. The American Rescue Plan Act of 2021 has provided funding for three significant awards totaling about $53 million, as part of the efforts.

Together, these investments will increase the number of eligible women and young children that WIC reaches, improve the level of care that they get throughout their involvement with the program, and assist to close long-standing gaps in maternal and child health.

Competitive Landscape

The major global players in the market include: Johnson & Johnson, Jiovio Healthcare, Pfizer Inc., GlaxoSmithKline Inc., Merck & Co., Inc., RAND Corporation, SYNAPSE Product Development, Siemens, Reckitt Benckiser Group Plc, Sanofi among others.

COVID-19 Impact Analysis

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war may affect the maternal health market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. It may be challenging for expectant mothers to get adequate prenatal and postnatal care if healthcare facilities are damaged or destroyed as a result of the conflict. Conflict zones' hospitals and clinics may be overburdened or unable to deliver proper care.

Artificial Intelligence Analysis:

Artificial intelligence (AI) is increasingly being used in the maternal health market to improve various aspects of data analysis. A pregnant woman's medical history, health information, and lifestyle choices can be analyzed by AI algorithms to identify potential risk factors and forecast difficulties during pregnancy. This enables medical practitioners to develop individualized care regimens and intervene early.

Pregnant women can remotely monitor their health due to wearable technology and mobile apps that are powered by AI. These gadgets can monitor fetal movements, contraction patterns, and other pertinent information, alerting medical professionals if any unsettling trends are found.

By Treatment

  • Hormones
  • Nutritives
  • Analgesics
  • Anti-Infectives
  • Others

By Indication

  • Miscarriage
  • Premature Labor and Birth
  • Others

By Distribution channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In March 2023, MedArrive, the top mobile-integrated care management solution, announced a partnership with Ouma Health, a provider of whole maternity telehealth services, in order to provide complete maternal-fetal care to at-risk women on Medicaid. By including a crucial service into MedArrive's expanding ecosystem of specialized care providers that managed Medicaid health plans can utilize for members in their homes, the collaboration intends to improve the health of expectant mothers and their newborns, particularly those at high risk.

Why Purchase the Report?

  • To visualize the global maternal health market segmentation based on the treatment, indication, distribution channel, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of maternal health market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of critical products of all the major players.

The global maternal health market report would provide approximately 61 tables, 57 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment
  • 3.2. Snippet by Indication
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising collaboration among key players
    • 4.1.2. Restraints
      • 4.1.2.1. Challenges associated with maternal health
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological advancements
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Treatment

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.1.2. Market Attractiveness Index, By Treatment
  • 9.2. Hormones*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Nutritives
  • 9.4. Analgesics
  • 9.5. Anti-Infectives
  • 9.6. Others

10. By Indication

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.1.2. Market Attractiveness Index, By Indication
  • 10.2. Miscarriage*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Premature Labor and Birth
  • 10.4. Others

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.1.2. Market Attractiveness Index, By Distribution Channel
  • 11.2. Hospital Pharmacies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Retail Pharmacies
  • 11.4. Online Pharmacies

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.6.1. U.S.
      • 12.2.6.2. Canada
      • 12.2.6.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.6.1. Germany
      • 12.3.6.2. U.K.
      • 12.3.6.3. France
      • 12.3.6.4. Italy
      • 12.3.6.5. Spain
      • 12.3.6.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.6.1. Brazil
      • 12.4.6.2. Argentina
      • 12.4.6.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.6.1. China
      • 12.5.6.2. India
      • 12.5.6.3. Japan
      • 12.5.6.4. Australia
      • 12.5.6.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Product Benchmarking
  • 13.3. Company Share Analysis
  • 13.4. Key Developments and Strategies

14. Company Profiles

  • 14.1. Johnson & Johnson*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. Jiovio Healthcare
  • 14.3. Pfizer Inc
  • 14.4. GlaxoSmithKline Inc.
  • 14.5. Merck & Co., Inc.
  • 14.6. RAND Corporation
  • 14.7. SYNAPSE Product Development
  • 14.8. Siemens
  • 14.9. Reckitt Benckiser Group Plc
  • 14.10. Sanofi

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us